Medifast, Inc. provided earnings guidance for the second Quarter of 2024. The company expects second quarter 2024 revenue to be in the range of $150 million to $170 million and second quarter 2024 diluted EPS to be in the range of $0.05 to $0.40. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company?s LifeMD common stock investment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 USD | -1.38% | +12.75% | -61.71% |
Apr. 30 | Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance | MT |
Apr. 30 | Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.71% | 275M | |
+11.85% | 8.05B | |
+5.29% | 7.59B | |
+2.63% | 6.07B | |
-2.80% | 3.85B | |
-11.22% | 3.55B | |
-7.04% | 1.28B | |
-32.50% | 1.03B | |
+12.52% | 971M | |
-15.69% | 813M |
- Stock Market
- Equities
- MED Stock
- News Medifast, Inc.
- Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024